Arthur Tzianabos, Ph.D., June Lee, MD, FACCP, and Joseph Loscalzo, MD, PhD Join 5AM Ventures

News
2022
2021
Archive

September 12, 2022

Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress
September 12, 2022

IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma
September 9, 2022

Nouscom Strengthens Leadership Team with the Appointments of Sven Gogov, MD, as Chief Medical Officer and Maria Arce-Tomas, PhD, as VP, Head of Regulatory Affairs
September 8, 2022

Purigen Biosystems Expands Commercial Presence in European Union with Proteigene Distribution Agreement
September 6, 2022

Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer
September 6, 2022

IDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma
September 6, 2022

New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living With Acromegaly
September 2, 2022

South Carolina Department of Corrections and Pear Therapeutics Team Up to Support Inmates in Recovery from Substance Use Disorders
August 29, 2022

Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial
August 29, 2022

IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-in-Class Pol Theta Helicase Inhibitor Development Candidate

© 2022 5AM Venture Management LLC